Deadline Extended: Special Issue on the Future of Cancer Screening: Leveraging AI and Precision Oncology

AI in Precision Oncology is pleased to announce a call for papers for an upcoming special issue focused on the future of cancer screening by leveraging AI technologies. Due to the critical role that early detection plays in improving cancer outcomes, this special issue collection is aimed at featuring research that has the capability of positively improving patient outcomes. Cancer remains a leading cause of mortality worldwide, and timely screening can significantly increase the chances of successful treatment and survival. 

Artificial intelligence (AI) has emerged as a powerful tool in enhancing the accuracy and efficiency of cancer screening processes. By dedicating a special issue to this topic, the journal will provide a platform for researchers, clinicians, and AI experts to showcase their cutting-edge developments, share innovative approaches, and address challenges related to AI-driven cancer screening. 

This special issue not only fosters collaboration and knowledge exchange but also accelerates the translation of AI advancements into clinical practice, ultimately benefiting patients by facilitating earlier cancer detection and more personalized treatment strategies.

This special issue will consider articles from the full breadth of evidence and especially Review Articles and Research Papers. For more details on each article type, please see submission guidelines. 

• Review Articles: Comprehensive reviews of the current state-of-the-art in AI-driven cancer screening. These articles should provide an overview of existing methods, their limitations, and the challenges in implementing AI in cancer screening, as well as potential future directions.
• Research Papers: A structured systematic investigation or study in cancer screening using AI technology. The research should contribute new knowledge, insights, or perspectives in the field. The primary purpose of a research paper is to communicate the research process, methods, results, and conclusions to the academic community.
• Front Matter: Innovative and forward-thinking perspectives, commentaries, and opinion pieces unique to our field that combine all aspects of technology and medicine within the context of cancer screening and AI tools.

Areas of interest include, but are not limited to AI in cancer screening, current practice, gaps, and where future innovation should focus in the following areas:  

• Colorectal cancer 
• Breast cancer 
• Cervical cancer 
• Lung cancer 
• Skin cancer 
• Prostate cancer

Additional areas of interest include:

• Wearables and cancer screening
• Multicancer early detection: how AI and precision oncology are revolutionizing cancer screening
• Personalized screening plans: AI role in identification of patient at higher risk for malignancy
• Ethical consideration and strategies to ensure diversity in AI screening solution. 
• Integration with Clinical Practice: how to best assure the integration of AI-driven screening tools into routine clinical practice, addressing issues such as cost effectiveness, workflow integration, user-friendliness, and the role of healthcare professionals including human machine interactions
• In todays’ complex healthcare systems, what discerning criteria and deliberative considerations must be employed to judiciously choose an AI-based solution

We invite researchers and experts in these fields to submit their manuscripts to contribute to this important and groundbreaking special issue. We also encourage submission of papers that have been published in conference proceedings, with the requirement that the authors have made significant extensions as compared to the already published version of the study.
 
Benefits of publishing in AI in Precision Oncology include:

• Expert peer review and editorial oversight of your manuscript from leading specialists in your field
• Zero-embargo green open access
• Free 30-day post-publication access to share your published research with your networks and colleagues
• Global visibility in more than 170 countries worldwide  
• Gold open access options available